AIIMS doctors are developing a cost-effective antibody-based cellular therapy for multiple myeloma. This innovative approach aims to make CAR-T cell therapy more accessible in India. The therapy targets BCMA, a protein found in myeloma cells, and has shown promise in animal models. Phase-1 clinical trials are planned to assess safety and efficacy.
